1. Home
  2. PUMP vs OMER Comparison

PUMP vs OMER Comparison

Compare PUMP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProPetro Holding Corp.

PUMP

ProPetro Holding Corp.

N/A

Current Price

$10.17

Market Cap

1.0B

Sector

Energy

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$17.60

Market Cap

844.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PUMP
OMER
Founded
2007
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
844.6M
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
PUMP
OMER
Price
$10.17
$17.60
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$14.14
$32.50
AVG Volume (30 Days)
3.0M
1.5M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
100.76
98.15
EPS
N/A
0.77
Revenue
$1,269,158,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.61
$233.22
P/E Ratio
N/A
$22.30
Revenue Growth
N/A
N/A
52 Week Low
$4.64
$3.94
52 Week High
$18.50
$19.65

Technical Indicators

Market Signals
Indicator
PUMP
OMER
Relative Strength Index (RSI) 37.98 49.27
Support Level $10.28 $10.16
Resistance Level $10.55 $17.65
Average True Range (ATR) 0.54 0.82
MACD -0.04 -0.45
Stochastic Oscillator 5.83 21.47

Price Performance

Historical Comparison
PUMP
OMER

About PUMP ProPetro Holding Corp.

ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: